RSS

Akcea Therapeutics

Akcea Therapeutics and Ionis Pharmaceuticals have announced that Tegsedi (inotersen) has received European marketing authorisation approval for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hATTR more

News

Akcea Therapeutics, has announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending the use of its orphan drug for the treatment of Stage 1 or Stage 2 polyneuropathy in adults with hereditary more

News

The UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has granted a positive opinion to Akcea Therapeutics’ volanesorsen for the treatment of familial chylomicronaemia syndrome (FCS) under the Early Access to Medicines Scheme (EAMS). more

News